A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration

British Journal of Ophthalmology

Volumn 100, Issue 7, 2016, Pages 914-917

  Chin Yee, David ^a   Eck, Thomas ^a   Fowler, Susan ^a   Hardi, Angela ^a   Apte, Rajendra S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DATA ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VISUAL ACUITY; COMPLICATION; DIAGNOSTIC IMAGING; DOSE RESPONSE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; RETINA; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; RANIBIZUMAB; RETINA; RETINAL NEOVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84946887763     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-306987     Document Type: Review

References (12)

1. Bressler NM, Chang TS, Suñer IJ, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56
2. Rakic JM, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study. Clin Ophthalmol 2013;7:1849-58
3. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48
4. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58
5. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-80
6. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50
7. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013;120(5 Suppl):S3-7
8. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30
9. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
10. Brown DM, Tuomi L, Shapiro H. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 2013;33:23-34
11. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
12. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411